Compare Mesoblast Limited (MESO) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Tripadvisor Inc Common Stock — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Tripadvisor Inc Common Stock trades at $8.68 (market cap $1.01B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is more actively traded (239,027 versus 3,004,748). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| MESO | TRIP | |
|---|---|---|
Market Cap | $1.75B | $1.01B |
Volume | 239,027 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $16.72 |
52-Week Low | $13.19 | $8.04 |
Typical Hold Time | 15 Days | 57 Days |
Enterprise Value | $1.83B | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
TripAdvisor (TRIP) trades at $8.96, up 3.82% today but near 52-week lows, with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported Q2 2026 earnings of $0.35 per share, missing estimates, while revenue trends show modest growth from $1.5B in 2022 to $1.9B in 2025. Analyst consensus is mixed with 62.5% hold ratings and a $13.58 price target, representing 52% upside potential from current levels.
The investment case hinges on TripAdvisor's ability to stabilize its core business amid AI disruption in travel planning. While valuation appears reasonable with P/S of 0.57 and EV/EBITDA of 6.28, recent earnings misses and competitive pressures from AI platforms create significant headwinds. The stock offers substantial upside if management can execute on growth initiatives, but faces execution risk in a rapidly evolving travel technology landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
